ASCO

The HER2-targeted bispecific investigational antibody zanidatamab, either as monotherapy or in combination with chemotherapy, has shown promising antitumor activity in an ongoing clinical trial of patients with HER2-expressing biliary tract cancer or gastroesophageal adenocarcinoma. Read More ›

Final results from the phase 3 clinical trial ClarIDHy showed that ivosidenib (Tibsovo), a first-in-class oral inhibitor of isocitrate dehydrogenase 1 (IDH1) mutation, prolonged the median overall survival (OS) in patients with previously treated advanced cholangiocarcinoma (CCA) and IDH1 mutation. Read More ›

A Call to Focus on Financial Toxicity and Quality of Life in Genitourinary Malignancies
San Francisco, CA—Delivering the keynote address at the 2020 Genitourinary Cancers Symposium, David F. Penson, MD, MPH, MMHC, Hamilton and Howd Chair in Urologic Oncology, Vanderbilt University Medical Center, Nashville, TN, highlighted the need to move toward patient-centered decisions beyond survival, focusing on patient-­centered outcomes by integrating quality of life (QOL) and financial toxicity into the shared, treatment-related, decision-making process. Read More ›

Studies Show ACA Reduces Disparities and Increases Access to Earlier Diagnosis and Treatment
Chicago, IL—Results from a new clinical trial suggest that limited access to care is the main contributing factor to the disparities in outcomes that exist between African American patients and white patients with cancer. Read More ›

What the Next Generation of Cancer Biomarkers May Involve
Dr Sanjiv Agarwala predicts that the cancer biomarkers of the future may be “mobile biomarkers,” meaning measures of the tumor microenvironment or immune response that change with therapy and may be able to determine treatment efficacy. Read More ›

How MSI and TMB Factor into Current Biomarker Testing Panels
Dr Sanjiv Agarwala discusses the usefulness of MSI and TMB as novel biomarkers for various cancer types. His argument is that the first FDA approval of a therapy based on MSI rather than tumor type makes this biomarker useful, but TMB is not yet ready for “prime time.” Read More ›

Best Practices in How Oncologists and Pathologists Can Work Together to Optimize Biomarker Testing for their Patients with Cancer
Dr Sanjiv Agarwala describes best practices developed at St. Luke’s Cancer Center, where a committee has been formed in which clinicians and pathologists meet to reach consensus on reflex testing of molecular biomarkers, as well as the value of biomarker testing in enhancing patient care. Read More ›

Biomarker Data in Melanoma Presented at ASCO 2018 Are Largely Extensions of Previous Studies Rather Than New Discoveries
Dr Sanjiv Agarwala argues that much of the biomarker data in melanoma presented at ASCO 2018 are around the value of PD-L1 testing; however, even PD-L1–negative melanoma patients seem to respond to anti–PD-1 therapy, although some studies suggest PD-L1–negative patients may be better candidates for combination immunotherapy. Read More ›

How Real-World Data Are Consolidating Our Knowledge Regarding Melanoma Treatment
Dr Sanjiv Agarwala reviews real-world data presented at ASCO 2018 on immunotherapy of melanoma that serve to reassure providers regarding current treatment approaches, but do not offer any significant practice-changing results. Read More ›

The Greatest Challenges in Incorporating Biomarkers into Cancer Care
Dr David Spigel discusses challenges and solutions to incorporating cancer biomarkers into patient care, including finding pathology resources to do the testing, issues around reimbursement, and educating colleagues on the value and operational aspects of biomarker testing in delivering personalized therapy to patients with cancer. Read More ›

Page 1 of 2


Subscribe to The Oncology Nurse-APN/PA

To sign up for our newsletter or print publications, enter your contact information below.

I'd like to receive: